The PSA Screening for HIM Act (H.R. 1300/S. 297)
The PSA Screening for HIM Act (H.R. 1300/S. 297) would remove out-of-pocket costs for prostate cancer screening for those at highest risk for the disease.
Black Men and Prostate Cancer
November 5, 2025
After declining through much of the late 2000s and early 2010s, prostate cancer incidence rates have risen for nearly a decade. The increase includes distant-stage disease diagnoses among men of all ages, climbing by nearly 3% annually among those younger than 55 years. Some men are at a higher risk of developing prostate cancer than others, including African American men and men who have a first-degree relative (i.e., a parent, sibling, or child) who has been diagnosed with prostate cancer.
Prostate cancer remains the most commonly diagnosed cancer among Black men in the United States, with an estimated 57,300 cases expected in 2025, accounting for 44% of all cancer diagnoses in Black men. Black men have the highest prostate cancer death rate than any other racial or ethnic group, and are over twice as likely to die from prostate cancer than White men. This large disparity in prostate cancer deaths reflect less access to high-quality treatment options; and evidence suggests that Black men have equivalent or higher prostate cancer-specific survival rates when they are treated within an equal-access health care system such as the Veterans Health Administration.
The good news is deaths from prostate cancer have been declining, in part due to improvements in treatment,
management of recurrent disease, and early detection with a prostate-specific antigen (PSA) test. Among Black men, prostate cancer deaths have dropped by 56% since their peak in 1993.